Fig. 7From: EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinomaPotential regulate mechanisms of EFNA3 in LUAD. A GO analysis of 168 purple module eigengenes; BP: biological processes; CC: cellular components; MF: molecular functions; B KEGG analysis of purple module eigengenes; C Enriched pathways in the EFNA3-high and EFNA3-low group based on GSEA analysisBack to article page